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Abstract
Background: Hepatocellular carcinoma (HCC) displays high resistance to conventional chemotherapy. Considering
that microRNA-122 (miR-122) performs an essential function to promote chemosensitivity of HCC cells, an effective
vehicle-mediated miR-122 delivery may represent a promising strategy for HCC chemotherapy. An increasing
interest is focused on the use of exosomes as biological vehicles for microRNAs (miRNA) transfer. Mesenchymal
stem cells (MSCs) are known for their capacity to produce large amounts of exosomes. This study aimed to
determine whether adipose tissue-derived MSC (AMSC) exosomes can be used for miR-122 delivery.
Methods: AMSCs were transfected with a miR-122 expression plasmid. At 48 h after transfection, AMSC-derived
exosomes (122-Exo) were harvested and added to recipient HCC cells. Expression levels of miR-122 in AMSCs,
exosomes, and HCC cells were quantified by real-time PCR. The mRNA and protein levels of miR-122-target genes
in recipient HCC cells were quantified by real-time PCR and Western blot, respectively. The effects of 122-Exo on
cell viability, apoptosis, and cell cycle of HCC cells were evaluated by MTT and flow cytometry analysis. Xenograft
models were used to determine whether 122-Exo can sensitize HCC cells to sorafenib in vivo.
Results: Data showed that miR-122-transfected AMSC can effectively package miR-122 into secreted exosomes,
which can mediate miR-122 communication between AMSCs and HCC cells, thereby rendering cancer cells
sensitive to chemotherapeutic agents through alteration of miR-122-target gene expression in HCC cells. Moreover,
intra-tumor injection of 122-Exo significantly increased the antitumor efficacy of sorafenib on HCC in vivo.
Conclusions: The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to
enhance HCC chemosensitivity.
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Background
Most hepatocellular carcinoma (HCC) patients are diag-
nosed at intermediate advanced stages, during which the
only proven therapies are transarterial chemoembolization
(TACE) and targeted therapy with the multikinase inhibi-
tor, sorafenib [1]. However, HCC displays high resistance
to commonly used chemotherapeutic agents, such as 5-
fluorouracil (5-FU) and doxorubicin. Therefore, the
discovery of new targets and the development of novel
therapeutic approaches to enhance HCC chemosensitivity
are urgently needed.
At present, certain progress is being developed in the
abovementioned field [2, 3]. Several studies have indicated
that non-coding RNA, such as long non-coding RNAs
and microRNAs (miRNAs), participate in cancer develop-
ment and perform important functions in diagnosis and
prognosis [4–6]. Moreover, miRNAs are determined to be
correlated with chemosensitivity in cancers [7, 8]. The
liver-specific microRNA-122 (miR-122) has been found to
perform multiple functions in liver physiology and path-
ology [9]. Notably, the loss or downregulation of miR-122
has been associated with HCC development and
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progression [10] and is closely related to poor prognosis
and metastasis of HCC [11]. Increasing evidence indicates
that miR-122 can modulate the chemosensitivity of HCC
cells [12]. Ectopic expression of miR-122 in non-
expressing HepG2 and Hep3B cells can inhibit tumori-
genic properties, such as growth, invasion, and tumor
formation in nude mice, as well as can sensitize these cells
to doxorubicin and sorafenib [13, 14].
However, a safe and effective vehicle for miR-122 de-
livery also is a key factor in miR-122-mediated chemo-
therapy sensitization. Growing interest is focused on the
use of exosomes as biological delivery vehicles for
miRNA transfer, as exosomes do not elicit acute im-
mune rejection and risk tumor formation [15]. Further-
more, exosomes can be manufactured in culture by
incorporating therapeutic miRNAs into exosome-
producing cells, thereby possibly enabling personalized
treatment [16]. Among the cell types known to produce
exosomes, human mesenchymal stem cells (MSCs) are
the most prolific producers [17]. Infusion of human
MSC-derived exosomes into an immunocompetent
mouse model of acute myocardial ischemia has been
shown to be therapeutically effective and lacking of evi-
dent adverse effects [18].
Adipose tissue-derived MSCs (AMSCs) represent a
highly advantageous tool for stem cell-based therapy
[19]. The current study investigated whether exosome-
mediated transfer of miR-122 via miRNA-modified
AMSCs can enhance the chemosensitivity of HCC cells.
Results
AMSCs package miR-122 into secreted exosomes
AMSCs positively expressed CD29, CD44, CD73, CD90,
and CD105 but negatively expressed CD31, CD34,
CD45, and HLA-DR. Positive staining of Oil Red O or
Alcian Blue was observed after adipogenic induction of
AMSCs for 14 days or chondrogenic induction for
28 days, respectively (Fig. 1).
AMSCs were transfected with a plasmid encoding for
miR-122 or for cel-miR-67 (Caenorhabditis elegans miR-
67) as control. At 48 h after transfection, extracellular
exosomes were isolated from the AMSCs supernatant.
AMSC-derived exosomes showed the positive expression
of exosomal markers, such as CD9, CD63, and CD81
[17, 20] (Fig. 2a). Afterward, miR-122 expression was
measured in AMSCs and exosomes. The expression of
miR-122 was 39.7 ± 1.3-fold and 21.6 ± 3.4-fold higher in
miR-122-transfected AMSCs (AMSC-122) and their
exosomes (122-Exo) than that of miR-122 in cel-miR-
67-transfected AMSCs (AMSC-67) and their exosomes
(67-Exo), correspondingly (Fig. 2b, c). These data dem-
onstrate that AMSCs can efficiently package plasmid-
expressed miR-122 into secreted exosomes.
Exosomes mediate miR-122 communication between
AMSCs and HCC cells
AMSC-122 cells were labeled with a phospholipid mem-
brane dye, DilC16 (3), to trace the derived exosomes.
After culturing for an additional 48 h, fluorescent exo-
somes were collected and added to recipient HepG2 cells.
Confocal imaging revealed the delivery of labeled exo-
somes as indicated by the presence of the fluorescent
membrane in unlabeled recipient HepG2 cells (Fig. 2e, f ).
As a further proof, the expression of miR-122 was
10.5 ± 1.4-fold higher in 122-Exo-treated HepG2 cells
than that in 67-Exo-treated cells (Fig. 2d). Thus,
AMSC-derived exosomes can deliver miR-122 into
HCC cells in vitro.
122-Exo alters target gene expression in HCC cells
To examine whether 122-Exo mediated-miR-122 com-
munication can alter the expression of miR-122 target
genes, such as cyclin G1 (CCNG1), a disintegrin and
metalloprotease 10 (ADAM10), and insulin-like growth
factor receptor 1 (IGF1R) in hepatoma cells [13, 14],
HepG2 cells were exposed to 122-Exo or 67-Exo for
24 h. Both mRNA and protein levels of these genes were
downregulated in 122-Exo-treated HepG2 cells in com-
parison with 67-Exo-treated cells (Fig. 3).
These data suggest that miR-122, which is delivered
via AMSC exosomes, is functionally active in acceptor
HCC cells. Moreover, 122-Exo may potentially facilitate
the sensitivity of HCC cells to chemotherapeutic agents
by negative regulation of the expression of miR-122 tar-
get genes, which are involved in the drug resistance or
sensitivity of cancer cells.
122-Exo increases chemosensitivity of HCC cells
To determine whether 122-Exo affects the chemosensi-
tivity of hepatoma cells in vitro, HepG2 and Huh7 cells
were exposed to chemotherapeutic agents combined
with 122-Exo or 67-Exo. The growth inhibition of 5-FU
or sorafenib on HCC cells was not altered by 67-Exo
treatment, whereas the inhibitory effect of 5-FU or so-
rafenib on 122-Exo-treated HCC cells significantly in-
creased in comparison with 67-Exo-treated control,
particularly on HepG2 cells (Fig. 4a).
Flow cytometric analysis with Annexin V/PI staining
also revealed an increase of apoptotic cells among 122-
Exo-treated HCC cells, especially in HepG2 cells, rela-
tive to 67-Exo-treated cells (Fig. 4b, c). The apoptotic
rate between 67-Exo-treated and chemotherapeutic
agent only-treated HCC cells presents no difference.
Subsequently, we tested whether cell cycle arrest con-
tributed to the enhanced growth inhibition by 122-Exo
treatment. As shown in Fig. 4e, treatment of HepG2
cells with 122-Exo resulted in an increase in the percent-
age of G0/G1 population from 67.0 ± 1.6 % (5-FU) and
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63.4 ± 1.1 % (sorafenib) to 80.4 ± 1.7 % (122-Exo and 5-
FU) and 74.7 ± 3.1 % (122-Exo and sorafenib) with 5-FU
or sorafenib exposure, respectively. Moreover, the treat-
ment of Huh7 cells with 122-Exo showed similar G0/G1
arrest trends.
These data indicate that exosomes from miR-122-
modified AMSCs can increase the chemosensitivity of
HCC cells by enhancing cell apoptosis and cell cycle
arrest.
122-Exo sensitizes HCC cells to sorafenib in vivo
Finally, to determine whether 122-Exo could sensitize hepa-
toma cells to chemotherapeutic agents in vivo, AMSC-
derived exosomes (50 μg total protein in 10 μl volume)
were administered to nude mice bearing HepG2 cells com-
bined with sorafenib treatment. One intra-tumor injection
of 122-Exo at 7 days after subcutaneous inoculation signifi-
cantly reduced the tumor volume and weight compared
with 67-Exo or vehicle-treated control. The tumor volume
Fig. 1 Identification of human adipose tissue-derived mesenchymal stem cells (AMSCs). a Flow cytometry analysis of the surface markers in
AMSCs. b Cellular morphology of AMSCs in culture. c Oil Red O staining in AMSCs cultured in adipogenesis differentiation medium for 14 days.
d Alcian Blue staining in AMSCs cultured in chondrogenesis differentiation medium for 21 days. Scale bar = 50 μm
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Fig. 3 122-Exo alters miR-122-target genes expression in HepG2 cells. a mRNA expression levels of miR-122-targeted genes in HepG2 cells treated
with exosomes. b Western blot analysis of miR-122-targeted genes in HepG2 cells treated with exosomes. c–e Relative protein expression levels
of CCNG1, ADAM10, and IGF1R in exosome-treated HepG2 cells. Data are presented as means ± SE. (*p < 0.05, n = 3). U.T untreated, 122-Exo
AMSC-122-derived exosomes, 67-Exo AMSC-67-derived exosomes
Fig. 2 Exosome-mediated miR-122 communication between AMSCs and HepG2 cells. a Western blot for CD9, CD63, and CD81 expression in
AMSC-derived exosomes. b–d Real-time PCR detection of miR-122 expression in AMSCs (b), AMSC-derived exosomes (c), and exosome-treated
HepG2 cells (d). e, f Confocal images of AMSC-122 stained with DilC16(3), a phospholipid membrane dye. Transfer of fluorescent exosomes from
AMSC-122 is apparent in HepG2 cell membranes and cytoplasm. Data are presented as means ± SE. (*p < 0.05, n = 3). AMSC-122 miR-122-transfected
AMSC, AMSC-67 cel-miR-67-transfected AMSC, Media precipitates from AMSC-conditioned media, Exo naïve AMSC-derived exosomes, 122-Exo
AMSC-122-derived exosomes, 67-Exo AMSC-67-derived exosomes. Scale bar = 20 μm
Lou et al. Journal of Hematology & Oncology  (2015) 8:122 Page 4 of 11
Fig. 4 (See legend on next page.)
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and weight showed no difference between naïve exosome-
or vehicle-treated mice at 28 days after exosome adminis-
tration and sorafenib treatment (Fig. 5a, b). Real-time poly-
merase chain reaction (PCR) and Western blot analysis also
showed that the expression of CCNG1, IGF1R, and
ADAM10 gene was downregulated in 122-Exo-treated tu-
mors in comparison with 67-Exo-treated cells (Fig. 5d, e).
The expression of apoptosis-related genes, Caspase 3 and
Bax (Bcl-2 Associated X protein), was upregulated in the
122-Exo-treated group. However, treatment with AMSC-
derived exosomes alone presented no effect on HCC
growth. As shown in Fig. 6, no statistically significant differ-
ence was observed between exosome-treated groups and
vehicle group in terms of the tumor volumes and weights
at 28 days after exosome administration alone (without
combination with sorafenib).
Overall, these results revealed that 122-Exo adminis-
tration promotes the growth inhibitory property of so-
rafenib toward HCC cells.
Discussion
Exosomes are nanometer-sized vesicles of endocytic origin
that are released by multiple cell types. Exosomes essen-
tially exert their functions as mediators of intercellular
communication by transferring protein and RNA. Thus,
the use of exosomes as biological delivery vehicles is of
considerable interest [21, 22]. Increasing studies indicate
that MSCs are well suited for the mass production of exo-
somes [17], which may perform important functions in
the therapeutic effect of MSCs through paracrine mechan-
ism. MSCs have been reported to potentially regulate
neurite outgrowth by exosome-mediated transfer of miR-
(See figure on previous page.)
Fig. 4 122-Exo sensitizes HCC cells to chemotherapeutic agents. a Cell viability assay on HepG2 and Huh7 cells by combined treatment with
chemotherapeutic agents and AMSC-derived exosomes. b FITC-Annexin V/PI assay in exosome-treated HCC cells after 5-FU treatment. c FC analysis for
Annexin V revealed an increase in apoptotic cells in 122-Exo-treated HCC cells after 5-FU or sorafenib exposure. d, e Cell cycle analysis revealed an
increase in G0/G1 population in 122-Exo-treated HepG2 cells after 5-FU or sorafenib exposure. Data are presented as means ± SE. (*p < 0.05, **p < 0.01,
n = 3). U.T untreated, 122-Exo AMSC-122-derived exosomes, 67-Exo AMSC-67-derived exosomes
Fig. 5 Intra-tumor injection of 122-Exo sensitizes HCC cells to sorafenib in vivo. a, b Tumor volume a and weight b measurement of HepG2
xenograft tumors at 35 days post-implantation (28 days after exosome administration combined with sorafenib treatment). c Imaging of mice at
35 days post-implantation. d, e Real-time PCR (d) and Western blot (e) analyses of miR-122-targeted gene expression in tumor samples at 35 days
post-implantation. f Western blot analysis of apoptosis-related gene expression in the above tumor samples. Data are presented as means ± SE.
(*p < 0.05, n = 5). Exo naïve AMSC-derived exosomes, 122-Exo AMSC-122-derived exosomes, 67-Exo AMSC-67-derived exosomes
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133b to neural cells [23]. Further works show that exo-
somes derived from miR-146-expressing MSCs can deliver
miR-146 into glioma cells in vitro, as well as reduce gli-
oma xenograft growth in a rat model of primary brain
tumor [16]. The present study demonstrated a novel strat-
egy for increasing HCC chemosensitivity through AMSCs
exosome-mediated transfer of therapeutic miR-122. The
miR-122-modified AMSCs can effectively package miR-
122 into secreted exosomes, which mediate miR-122 com-
munication between AMSCs and HCC cells, thus further
increasing the sensitivity of HCC cells to chemotherapeu-
tic agents through alteration of miR-122-target gene ex-
pression in these cells.
Among the predicted targets of miR-122, ADAM10,
IGF1R, and CCNG1 play key roles in tumorigenesis and
drug sensitivity in various cancers. ADAM10 is associ-
ated with tumor progression and confers resistance to
doxorubicin-induced apoptosis in HCC cells by activa-
tion of the PI3-K/Akt pathway [24]. Signaling through
IGF1R regulates HCC initiation, progression, metastasis,
and resistance to therapy [25, 26]. Enhanced expression
of cyclin G1 (CCNG1) contributed to drug resistance of
hepatoma cells and increased recurrence rate in HCC
patients [12]. In vitro experiments indicated that 122-
Exo treatment resulted in the reduced expression of
these genes in HCC cells over time, even at 4 weeks
after122-Exo treatment (data not shown). In addition, an
increase in the G0/G1-phase population and a corre-
sponding decrease in the G2/M-phase, which is identi-
fied as a response to cyclin G1 knockdown [27], were
observed in 122-Exo-treated HepG2 cells combined with
chemotherapeutic agents. Therefore, by downregulating
the expression levels of target genes, exosomes from
miR-122-modified AMSCs can effectively increase the
chemosensitivity of HepG2 cells through the induction
of apoptosis and cell cycle arrest.
Given that systemic therapy with the multikinase in-
hibitor sorafenib is the standard of care for unresectable
or advanced-stage HCC [28], we further tested whether
122-Exo can synergize its inhibitory function in mice
model. A lower concentration of sorafenib (5 mg/kg)
than the previously reported amount [29] was used to
treat HepG2 xenograft tumors. One intra-tumor injec-
tion of 122-Exo significantly enhanced the growth
Fig. 6 Treatment with AMSC-derived exosomes alone has no effect on HCC growth in vivo. a, b Nude mice were inoculated subcutaneously with
HepG2 cells. After 7 days of tumor growth, AMSC-derived exosomes were directly administered via intra-tumor injection. Tumor volume (a) and
weight (b) measurement of HepG2 xenograft tumors at 35 days post-implantation (28 days after exosome administration). c Imaging of mice at
28 days after sole exosome treatment. Data are presented as means ± SE (n = 5). Exo naïve AMSC-derived exosomes, 122-Exo AMSC-122-derived
exosomes, 67-Exo AMSC-67-derived exosomes
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inhibition by sorafenib at reduced concentration. How-
ever, the function of MSC in tumor therapy remains
controversial [30]. Several studies have shown that MSC-
derived naïve MVs/exosomes can inhibit tumor growth in
mice models of ovarian cancer, hepatoma, multiple mye-
loma, and bladder tumors [31–34]. Another study
reported that MSC-derived exosomes can promote vascu-
larity and tumor growth in mice xenograft models of gas-
tric carcinoma and colon cancer [35]. We further tested
whether naïve AMSC-derived exosomes can affect tumor
growth. Naive exosomes were administered into nude
mice bearing HepG2 cells through one intra-tumor injec-
tion, and PBS was used as vehicle control. No significant
differences were observed between the two groups in
terms of tumor volume and weight at 28 days after exo-
some administration combined with (Fig. 5) or without
sorafenib treatment (Fig. 6). These data suggest that naïve
MSC-derived exosomes may not affect HCC growth and
chemosensitivity by themselves. The different effect of
MSC-derived exosomes on tumor growth between our
study and the above studies may be ascribed to differences
in tumor-bearing models, MSCs sources, and route for
exosome administration. Thus, the increased sensitivity of
HCC cells to sorafenib by 122-Exo administration de-
pends on exosome-mediated miR-122 transfer and down-
regulation of miR-122-target genes, which was reported to
be involved in the antitumor activity of sorafenib in vivo
[36, 37]. However, treatment with 122-Exo alone (without
combination with sorafenib) cannot significantly reduce
tumor volume and weight (Fig. 6). This effect may be
attributed to the possibility that without the growth re-
tardation effect of sorafenib, one intra-tumor injection of
122-Exo was insufficient for tumor growth inhibition.
The current study directly delivered exosomes into the
subcutaneous xenograft models via intra-tumor injec-
tion. A previous study demonstrated that by engineering
the dendritic cells to express an exosomal membrane
protein (Lamp2b) fused to αv integrin-specific iRGD
peptide, natural exosomes can be used for targeted
tumor therapy [38]. Additional work is needed to
characterize the delivery of exosomal miRNAs in ortho-
topic HCC models via systemic administration. More-
over, considering that the isolation of exosomes and the
culturing of MSCs include reagents and methods that
are still inappropriate for human use, safety data from
animal studies cannot ensure the safety of initial studies
in humans. Improvement in the methods for AMSC cul-
ture and exosome purification will increase the feasibility
and safety of AMSC-derived exosome therapy in clinical
applications.
Conclusions
Our data indicate that miR-122, which is delivered via
AMSC exosomes, can increase the sensitivity of HCC
cells to chemotherapeutic agents, thereby providing a
new treatment strategy for HCC.
Methods
Isolation and identification of AMSCs
Subcutaneous adipose tissues were obtained from three
female patients (32, 28, and 41 years old, respectively)
undergoing tumescent liposuction at the First Affiliated
Hospital in Hangzhou. This study was approved by the
hospital’s ethics committee, and informed consent was ob-
tained from each patients. Adipose tissue was processed
as previously described [39] and maintained in Mesen-
PRO® RS™ Medium (Gibco) containing 1 % antibiotic-
antimycotic (Gibco). The phenotype profile of AMSCs
(passages 3 to 6) was evaluated through flow cytometry
analysis (BD Accuri® C6 flow cytometer) by using PE-
labeled cluster designation 29 (CD29), CD31, CD44,
CD45, CD73, CD90, CD105, and human leukocyte
antigen-DR (HLA-DR) (BD Bioscience Pharmingen) anti-
bodies [39, 40]. IgG1 was used as isotype control. The dif-
ferentiation of AMSCs to chondrocytes and adipocytes
was tested by using StemPro® chondrogenesis and adipo-
genesis differentiation kit (Gibco). Afterward, staining
with Oil Red O and Alcian Blue was performed to detect
adipocytes and chondrocytes, respectively [41].
Cell culture
HepG2 cells were maintained in DMEM (Gibco) containing
10 % FBS (Gibco) and 1 % antibiotic-antimycotic.
Plasmids and AMSC transfection
The AMSC-conditioned medium consisted of DMEM
supplemented with 10 % fetal bovine serum (FBS) from
which bovine exosomes and protein aggregates were re-
moved by ultracentrifugation at 100,000 g and 4 °C for
16 h. Prior to transfection, 1 × 106 AMSCs were seeded
in 10 mL of AMSC-conditioned medium overnight.
AMSCs were then transfected with plasmids of hsa-
miR-122 or cel-miR-67, which contained no known
mRNA-binding targets in human (GenScript) by using
Lipofectamine™ 2000 (Invitrogen). At 48 h after transfec-
tion, AMSCs were harvested for real-time PCR analysis.
Isolation and identification of AMSC-derived exosomes
After 48 h of miRNA transfection, exosomes were isolated
from the AMSCs supernatant by using an ExoQuick-TC
Kit (System Biosciences, CA) in accordance with the man-
ufacturer’s instructions. These exosomes were then char-
acterized by Western blotting analysis of exosome surface
markers, such as CD9, CD63, and CD81 (Abcam). Precipi-
tates from AMSC-conditioned media were used as nega-
tive control. The protein content of exosomes was
determined by using BCA protein assay kit (Pierce).
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Subsequently, exosome pellets were resuspended in sterile
PBS at a total protein concentration of 5 μg/μL.
Isolation and detection of miRNA
Total RNA enriched with miRNAs was isolated from
AMSCs or exosomes by using a miRVana miRNA isola-
tion kit. Real-time PCR was then performed following
the manufacturer’s instructions (Ambion Diagnostics,
TX) to examine miR-122 expression. Data were normal-
ized over the average cycle threshold (CT) value of U6,
and 2-ΔΔCT method was used to determine the relative
miRNA expression.
Confocal microscopy studies
AMSCs were labeled with the phospholipid membrane
dye, lipophilic carbocyanine DilC16 (3) (1.25 μM) [42].
After 10 min of incubation at 37 °C, cells were washed
and resuspended in fresh media for 48 h. Fluorescent
exosomes were collected and added into recipient
HepG2 cells. Afterward, cells were fixed with methanol,
mounted on slides, and imaged via confocal microscopy
(Olympus). Background fluorescence was subtracted
using unstained cells.
RNA isolation and real-time PCR
Total RNA was isolated from HepG2 cells or tumor
samples by using TRIzol, followed by real-time PCR ana-
lysis with ABI Prism 7900 (Applied Biosystems, Foster
City, CA) to examine the expression of CCNG1,
ADAM10, and IGF1R. GAPDH was used as an internal
control. The 2-ΔΔCT method was employed to determine
the relative mRNA expression.
Western blot analysis
HepG2 cells or tumor samples were lysed with RIPA
peptide lysis buffer (Beyotime Biotechnology, Jiangsu,
China) containing 1 % protease inhibitors (Pierce). The
protein content of different fractions was detected via
BCA method. Equivalent amounts of protein (20 μg)
were separated by 10 % SDS-PAGE gels and transferred
to polyvinylidene difluoride membranes (Millipore,
Bedford, MA) and blocked with 1 % BSA in TBST for 1 h
at room temperature. The membrane was incubated with
CCNG1, IGF1R, ADAM10, Bax, Caspase 3, or GAPDH
(Abcam) antibodies overnight at 4 °C. After washing, the
membrane was incubated with HRP-conjugated secondary
antibody (1:3000; Huabio) for 1 h. Blots were visualized
via ECL-associated fluorography (Millipore).
Cell viability assay
HepG2 and Huh7 cells were plated in 96-well plates at
the concentration of 2 × 103/well and treated with 5-FU
or sorafenib combined with or without exosomes
(50 ng/μL). At 72 h after culture, cell viability was
determined by an 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2-H-tetrazolium bromide (MTT) assay (Sigma).
Flow cytometry analysis of cell apoptosis and cell cycle
Cells were plated in 6-well plates at the concentration
of 2 × 105/well and treated with 5-FU (10 μM) or so-
rafenib (5 μM) combined with or without exosomes
(50 ng/μL). At 48 h after treatment, cell apoptosis
and cell cycle were detected using an Annexin V/PI
detection kit (BD Biosciences) and cell-cycle staining
kit (MultiSciences), in accordance with the manufac-
turer’s instructions and then analyzed on a BD
Accuri® C6 flow cytometer.
Xenograft models and exosome treatment
Male Balb/c nude mice (6 weeks old) were purchased
from Zhejiang Academy of Medical Science. All experi-
mental procedures were conducted in accordance with
the Chinese legislation regarding experimental animals.
Mice were inoculated subcutaneously with HepG2 cells
(5 × 106). After 7 days of tumor growth, mice were ran-
domized into eight groups prior to exosome treatment.
The groups comprised four groups for sole exosome
administration and another four groups for exosome ad-
ministration combined with sorafenib treatment. Exo
(naive MSC-derived exosomes), 67-Exo (AMSC-67-de-
rived exosomes), or 122-Exo (AMSC-122-derived exo-
somes) suspension (50 μg total protein in 10 μL volume)
was directly administered via intra-tumor injection into
each mice (n = 5/group), respectively. PBS was used as
vehicle control. Sorafenib (5 mg/kg) was administered
by intraperitoneal (i.p.) injection for five consecutive
days of each week. Tumor volumes were calculated
using the following formula: tumor volume (mm3) =
0.5 × (W)2 × (L), where L represents the length and W
represents the width.
Statistical analysis
Differences between groups were analyzed by using con-
ventional Student’s t test or ANOVA. Each experiment
was repeated at least thrice, and data were presented as
mean ± SE (standard error). A p value of 0.05 or less was
considered as statistically significant.
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